Nobilis Reo+IB+G+ND

Authorised

- Avian reovirus, strains 1733 and 2408, Inactivated
- Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
- Infectious bursal disease virus, strain D78, Inactivated
- Newcastle disease virus, Inactivated

Product identification

Medicine name:
Nobilis Reo+IB+G+ND

Active substance:
Avian reovirus, strains 1733 and 2408, Inactivated

Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated

Infectious bursal disease virus, strain D78, Inactivated

Newcastle disease virus, Inactivated

Target species:
Chicken (for reproduction)

Route of administration:
Intramuscular use
Subcutaneous use

Product details

Active substance and strength:
Avian reovirus, strains 1733 and 2408, Inactivated
7.40 log2 enzyme-linked immunosorbent assay unit(s) / 1.00 dose

Infectious bronchitis virus, type Massachusetts, strain M41, Inactivated
6.00 log2 haemagglutination inhibiting unit(s) / 1.00 dose

Infectious bursal disease virus, strain D78, Inactivated
14.50 log2 virus neutralising unit(s) / 1.00 dose

Newcastle disease virus, Inactivated
50.00 50% Protective Dose / 1.00 dose

Pharmaceutical form:
Emulsion for injection

Withdrawal period by route of administration:
Intramuscular use:

- **Chicken (for reproduction)**
  - Meat and offal. 0 day

Mitte manustada vaktsiini munevatele kanadele. Mitte kasutada 4 nädala jooksul enne munemisperioodi algust.

Subcutaneous use:

- **Chicken (for reproduction)**
  - Meat and offal. 0 day

Mitte manustada vaktsiini munevatele kanadele. Mitte kasutada 4 nädala jooksul enne munemisperioodi algust.

Anatomical therapeutic chemical veterinary (ATCvet) codes:
QI01AA16

Legal status of supply:

Veterinary medicinal product subject to veterinary prescription

Authorisation status:
Valid

Authorised in:
Estonia

Package description:
Available only in Estonian
Available only in Estonian

Additional information

Entitlement type:
Marketing Authorisation

Legal basis of product authorisation:
Full application (Article 12(3) of Directive No 2001/82/EC)

Marketing authorisation holder:
Intervet International B.V.

Marketing authorisation date:
13/10/2005

Manufacturing sites for batch release:
Intervet International B.V.

Responsible authority:
State Agency Of Medicines

Authorisation number:
1338

Date of authorisation status change:
13/10/2005

To consult adverse reactions on veterinary medicinal products please go to www.adrreports.eu/vet

Documents

Summary of Product Characteristics

This document does not exist in this language (English). You can find it in another language below.